Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,389,629 papers from all fields of science
Search
Sign In
Create Free Account
CASC2 gene
Known as:
CANCER SUSCEPTIBILITY CANDIDATE 2
, CASC2
, cancer susceptibility candidate 2 (non-protein coding)
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
CASC1 gene
CASC3 gene
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Ginsenoside Rg3 suppresses the growth of gemcitabine‐resistant pancreatic cancer cells by upregulating lncRNA‐CASC2 and activating PTEN signaling
J. Zou
,
H. Su
,
C. Zou
,
Xiaodong Liang
,
Zhenghua Fei
Journal of biochemical and molecular toxicology
2020
Corpus ID: 211536722
Pancreatic cancer is one of the most fatal malignancies with high mortality. Gemcitabine (GEM)‐based chemotherapy is the most…
Expand
Highly Cited
2018
Highly Cited
2018
Downregulation of lncRNA CASC2 facilitates osteosarcoma growth and invasion through miR‐181a
Zhiwen Ba
,
L. Gu
,
Songnan Hao
,
Xiaofang Wang
,
Zhenping Cheng
,
Guangchen Nie
Cell Proliferation
2018
Corpus ID: 25737635
Long non‐coding RNA cancer susceptibility candidate 2 (CASC2) is a novel lncRNA and has been indicated as playing tumour…
Expand
2018
2018
Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a.
Yingxia Li
,
Shuai Lv
,
+4 authors
H. Wen
Biomedicine & pharmacotherapy = Biomedecine…
2018
Corpus ID: 53114055
2018
2018
Long noncoding RNA CASC2 regulates hepatocellular carcinoma cell oncogenesis through miR‐362‐5p/Nf‐κB axis
Liang Zhao
,
Yongjian Zhang
,
Yubao Zhang
Journal of Cellular Physiology
2018
Corpus ID: 23734621
The long non‐coding RNA segment cancer susceptibility candidate 2 (CASC2) has been shown to suppress tumor growth in a variety of…
Expand
Highly Cited
2017
Highly Cited
2017
Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin.
Yeqian Feng
,
Wen Zou
,
+6 authors
Lili Sun
Archives of Biochemistry and Biophysics
2017
Corpus ID: 3474745
Highly Cited
2017
Highly Cited
2017
Down-regulation of lncRNA CASC2 promotes cell proliferation and metastasis of bladder cancer by activation of the Wnt/β-catenin signaling pathway
Zhijun Pei
,
Xian Du
,
+9 authors
Jing Zeng
OncoTarget
2017
Corpus ID: 104087
Long noncoding RNAs cancer susceptibility candidate 2 (CASC2) have been demonstrated as playing crucial regulatory roles in a few…
Expand
2017
2017
Long noncoding RNA CASC2 inhibits metastasis and epithelial to mesenchymal transition of lung adenocarcinoma via suppressing SOX4.
D. Wang
,
Z-M Gao
,
L-G Han
,
XU F.
,
K. Liu
,
Y. Shen
European Review for Medical and Pharmacological…
2017
Corpus ID: 36583644
OBJECTIVE Recently, long non-coding RNAs (lncRNAs) have caught more attention for their role in tumor progression. Lung…
Expand
Highly Cited
2016
Highly Cited
2016
Long non-coding RNA CASC2 suppresses the proliferation of gastric cancer cells by regulating the MAPK signaling pathway.
Peng Li
,
Wanjiang Xue
,
Ying Feng
,
Q. Mao
American journal of translational research
2016
Corpus ID: 20703970
Long non-coding RNAs (lncRNAs) have been shown to play important roles in tumorigenesis. However, the biological functions and…
Expand
Highly Cited
2016
Highly Cited
2016
Low expression of long noncoding RNA CASC2 indicates a poor prognosis and regulates cell proliferation in non-small cell lung cancer
Xuezhi He
,
Zhili Liu
,
+5 authors
R. Guo
Tumor Biology
2016
Corpus ID: 23470928
Recently, long noncoding RNAs (lncRNAs) have been shown to have important regulatory roles in human cancer biology. The aim of…
Expand
Highly Cited
2015
Highly Cited
2015
Long non-coding RNA CASC2 suppresses malignancy in human gliomas by miR-21.
Ping Wang
,
Yunhui Liu
,
+4 authors
Yixue Xue
Cellular Signalling
2015
Corpus ID: 28937614
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE